🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
30.20
-2.34 (-7.19%)
Nov 20, 2026, 4:00 PM EST - Market closed

Nektar Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Nektar Therapeutics stock has a consensus rating of "Buy" and an average price target of $131.92. The average 1-year stock price forecast is 336.82% higher than the current stock price, while the lowest is $40 (+32.45%) and the highest is $192 (+535.76%).

Price Target: $131.92 (+336.82%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$40$131.92$149.5$192
Change+32.45%+336.82%+395.03%+535.76%

Analyst Ratings

The average analyst rating for Nektar Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy89991010
Buy111111
Hold112244
Sell000000
Strong Sell000000
Total101112121515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Buy
Reiterates
$153 → $149
BuyReiterates$153 → $149+393.38%Nov 16, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$185
BuyMaintains$185+512.58%Nov 16, 2026
Leerink Partners
Leerink Partners
Buy
Reiterates
$130
BuyReiterates$130+330.46%Nov 13, 2026
Wedbush
Wedbush
Hold
Maintains
$50 → $40
HoldMaintains$50 → $40+32.45%Nov 13, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$192
BuyMaintains$192+535.76%Nov 13, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
40.52M
from 55.23M
Decreased by -26.63%
Revenue Next Year
51.16M
from 40.52M
Increased by 26.26%
EPS This Year
-7.19
from -8.66
EPS Next Year
-9.93
from -7.19
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
101.91M92.06M90.12M98.43M55.23M40.52M
Revenue Growth
-33.36%-9.67%-2.10%9.22%-43.89%-26.63%
Gross Profit
77.01M70.42M56.35M67.74M55.23M40.52M
Gross Margin
75.57%76.50%62.53%68.82%100.00%100.00%
Operating Income
-446.10M-240.24M-135.23M-129.92M-130.77M-219.93M
Net Income
-523.84M-368.20M-276.06M-118.96M-164.08M-226.25M
EPS
-----8.66-7.19
Free Cash Flow
-----208.68M-216.85M
No. Analysts
-----15
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High54.4M
Avg40.5M
Low38.0M

Revenue Growth

Revenue Growth202620272028
High
-1.5%
Avg
-26.6%
Low
-31.2%

EPS Forecast

EPS202620272028
High-7.04
Avg-7.19
Low-7.33

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-